Market News Archive
Stay updated with the latest announcements
UCB: Reconstitution of the Board of Directors of the company
The company has informed that Bangladesh Bank, on August 27, 2024, dissolved the previous Board of the company and formed the new Board of Directors of the company. Subsequently, a Meeting of the Board of Directors of the company was held on August 29, 2024 and (cont.)
STANDBANKL: Dividend Disbursement
The company has informed that it has credited the Bonus Shares to the respective shareholders' BO Accounts and it has also disbursed the Cash Dividend to the respective shareholders for the year ended December 31, 2023.
FIRSTSBANK: Appointment of Chairman and Independent Directors
The company has informed that Bangladesh Bank has appointed Chairman and Independent Directors of First Security Islami Bank PLC. as under with effect from September 01, 2024: 01. Mr. Mohammad Abdul Mannan, Chairman & Independent Director, 02. Mr. Md. Azizur Rahman, Independent Director, 03. Mr. Md. Abdul Quddus, Independent Director, 04. Mr. Md. Saiful Alam, PhD, FCMA, Independent Director and 05. Mr. Md. Ragib Ahsan, FCA, Independent Director.
SHAHJABANK: Sale Declaration of a Sponsor
Mr. Tofazzal Hossain, a Sponsor of the Company, has expressed his intention to sell 7,35,729 shares out of his total holding of 1,56,78,954 shares of the company at prevailing market price (in the Public Market) through Dhaka Stock Exchange PLC. (DSE) within next 30 working days.
PADMALIFE: Q2 Financials
(Q2 Un-audited): As per life revenue account of the company for the period ended June 30, 2024: Balance of Life Insurance Fund was BDT (2,717,202,896) as on June 30, 2024 as against BDT (2,462,033,899) as on June 30, 2023. Total income was BDT 80,739,395 during April-June 2024 as against BDT 92,254,985 during April-June 2023. (cont.)
SIBL: Election of Chairman
The company has informed that the Board of Directors has elected Dr. M. Sadiqul Islam, FCMA as the Chairman of the Board of Directors of the company with immediate effect.
ASIAINS: Reschedule of AGM date
Refer to their earlier news disseminated by DSE on 19.08.2024 regarding postponement of AGM, the company has further informed that the AGM of the company will be held on September 17, 2024 at 12:00 noon by using digital platform.
ALLTEX: Regarding revaluation of land and land development of the company
The company has informed that the Board of Directors has decided to approve the revaluation report on Land and Land Development of the company submitted by A. Qasem & Co., Chartered Accountants, resulting in an increase of the company's total Land and Land Development value to Taka 218,82,00,000.00 from Taka 137,39,07,073.00 as of June 30, 2024, an increment of Taka 81,42,92,927.00 to be added to the Net Asset Value (NAV) of the company.
DSE NEWS: Time extension of private placement subs. of LB MULTI ASSET INCOME ETF
As per further application of LankaBangla Asset Management Company Limited, the private placement subscription period of the first ever Exchange Traded Fund at DSE, namely "LB MULTI ASSET INCOME ETF" has been extended upto 5.00 p.m. of September 03, 2024 by the registered Eligible Investors (EIs) through electronic subscription system of the stock exchanges. Minimum subscription amount is BDT 100,000 and maximum amount would be BDT 500,000,000. (cont.)
DSE NEWS: Awareness message
DSENEWS: All Stock Dealers, Stock Brokers and Authorized Representatives are asked to strictly follow the code of conduct as enumerated in the Second Schedule to the Securities and Exchange Commission (Stock Dealer, Stock Broker and Authorized Representative) Rules, 2000.
DSE NEWS: Awareness Message for Investors
DSE does not publish market data through any social media pages. INVESTORS should not rely on any information from an unauthorized source such as Facebook, WhatsApp, Viber, Linkedin etc. (cont.)
BSEC NEWS: Awareness Message for Investors
Investors are requested to consider the following facts at the time of making investment decision in the Capital Market: 1. Without acquiring proper knowledge, information and experience regarding different aspects and matters of Capital Market, one should not invest in the Capital Market. 2. The gain or loss, whichever comes from the investment, it belongs to you. So, well - thought of investment decision based on knowledge and fundamentals of the securities may be real assistance to you. (cont.)
DSE NEWS: Greetings Message
Honorable Investors, Good morning! Please make your investment decision based on Company fundamentals, technical analysis, price level and disclosed information. Avoid rumor-based speculations.
DSE NEWS: Daily Turnover of Main Board
Today's (02.09.2024) Total Trades: 233,467; Volume: 285,841,566 and Turnover: Tk. 10,655.435 million.
DSENEWS: Withdrawal of Authorized Representative
Withdrawal of Authorized Representative: One Securities Ltd. (DSE TREC No. 241) has withdrawn one of its Authorized Representatives, Mr. Atiqur Rahman with immediate effect.
DSENEWS: Withdrawal of Authorized Representative
Withdrawal of Authorized Representative: Shahjalal Islami Bank Securities Ltd. (DSE TREC No. 233) has withdrawn one of its Authorized Representatives, Mr. Md. Habibur Rahman with immediate effect.
DSENEWS: Withdrawal of Authorized Representatives
Withdrawal of Authorized Representatives: Sheltech Brokerage Limited (DSE TREC No. 120) has withdrawn two of its Authorized Representatives, i) Mr. Meskat Uddin and ii) Mr. Md. Ziaur Rahman with immediate effect.
DSENEWS: Withdrawal of Authorized Representative
Withdrawal of Authorized Representative: Rapid Securities Limited (DSE TREC No. 42) has withdrawn one of its Authorized Representatives, Mr. Md. Ziaul Haque with immediate effect.
RENATA: Regarding achieving EU DCP Approval for Cabergoline 0.5 mg Tablets
The company has informed that it has achieved successful approval of Cabergoline 0.5 mg tablets under the EU Decentralized Procedure (DCP). This approval comes with access to several European markets such as Ireland, France, Portugal, Italy, Denmark, Sweden, Netherlands, Norway, and Spain. Cabergoline, a dopamine agonist, is primarily used in the treatment of conditions such as hyperprolactinemia and Parkinson's disease. Cabergoline 0.5 mg will be manufactured at Renata's state-of-the-art (cont.1)
TB2Y0325: Suspension for Record date
Trading of 2Y BGTB 05/03/2025 Government Securities will be suspended on record date i.e., 04.09.2024 and day before the record date i.e., 03.09.2024. Trading of the Government Securities will resume on 05.09.2025.